ANI Pharmaceuticals, Inc. (ANIP) Receives Consensus Rating of “Hold” from Analysts
Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) have been given a consensus recommendation of “Hold” by the seven brokerages that are currently covering the company, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $65.33.
A number of brokerages recently issued reports on ANIP. Roth Capital set a $56.00 target price on shares of ANI Pharmaceuticals and gave the company a “hold” rating in a research report on Saturday, May 6th. BidaskClub upgraded shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday. Canaccord Genuity reiterated a “buy” rating and issued a $60.00 target price on shares of ANI Pharmaceuticals in a research report on Wednesday, August 9th. ValuEngine lowered shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. Finally, Guggenheim reissued a “buy” rating and issued a $80.00 price target on shares of ANI Pharmaceuticals in a report on Tuesday, July 4th.
Shares of ANI Pharmaceuticals (ANIP) opened at 46.02 on Tuesday. ANI Pharmaceuticals has a 52 week low of $42.23 and a 52 week high of $69.85. The firm has a market cap of $535.58 million, a PE ratio of 100.70 and a beta of 3.08. The company has a 50 day moving average of $46.52 and a 200 day moving average of $49.58.
ANI Pharmaceuticals (NASDAQ:ANIP) last announced its earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported $0.98 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.79 by $0.19. The firm had revenue of $44.80 million during the quarter, compared to analyst estimates of $43.20 million. ANI Pharmaceuticals had a net margin of 3.35% and a return on equity of 22.70%. ANI Pharmaceuticals’s revenue was up 43.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.11 EPS. On average, equities research analysts anticipate that ANI Pharmaceuticals will post $3.84 EPS for the current fiscal year.
Large investors have recently modified their holdings of the stock. Icon Advisers Inc. Co. acquired a new stake in shares of ANI Pharmaceuticals during the first quarter worth $1,025,000. Tudor Investment Corp ET AL increased its stake in shares of ANI Pharmaceuticals by 80.4% in the first quarter. Tudor Investment Corp ET AL now owns 8,300 shares of the specialty pharmaceutical company’s stock worth $411,000 after buying an additional 3,700 shares during the last quarter. Kennedy Capital Management Inc. acquired a new stake in shares of ANI Pharmaceuticals during the first quarter worth $4,069,000. Dimensional Fund Advisors LP increased its stake in shares of ANI Pharmaceuticals by 90.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 91,514 shares of the specialty pharmaceutical company’s stock worth $5,548,000 after buying an additional 43,534 shares during the last quarter. Finally, Prudential Financial Inc. increased its stake in shares of ANI Pharmaceuticals by 1.4% in the first quarter. Prudential Financial Inc. now owns 14,080 shares of the specialty pharmaceutical company’s stock worth $697,000 after buying an additional 200 shares during the last quarter. 55.63% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY WARNING: This news story was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of international trademark and copyright laws. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/08/22/ani-pharmaceuticals-inc-anip-receives-consensus-rating-of-hold-from-analysts.html.
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.
Receive News & Ratings for ANI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.